NCT06403800

Brief Summary

Artisanal, small-scale mining (ASM) is a large and essential component of the world's economy. Despite attendant risks, there is little research into risks to the health of artisanal miners. The tanzanite gemstone is mined exclusively in Northern Tanzania, in deep shafts using ASM techniques. There is concerning evidence that the burden of silicosis and tuberculosis (TB) amongst miners is high. In addition to miners' personal risks, there is concern that a high rate of silicotuberculosis may hamper community control of TB. Our primary aim is to measure the rate of silicosis progression among tanzanite miners. Our secondary aims include measuring the prevalence of TB among miners, describing TB transmission patterns in miners and the community, and assessing rates of 'catastrophic' economic loss amongst miners. To do this, the investigators propose two studies. First, the investigators will establish a prospective cohort of 410 small scale tanzanite miners and record symptoms, respiratory function including spirometry, chest radiography, and prevalence of TB and Human Immunodeficiency Virus (HIV) infection over an 18-month period. Second, the investigators will utilize an ongoing community-based TB screening program to perform a cross-sectional survey of TB prevalence among miners and community members. To assess TB transmission, the investigators will collect epidemiological data and perform whole genome sequencing (WGS) on positive Mycobacterium tuberculosis (MTb) culture samples. Given the lack of research and large global ASM workforce, 1 million of whom are in Tanzania, the results of this study will assist in the development and introduction of interventions to reduce the risks to respiratory health of artisanal mining in Tanzania and elsewhere; and provide ample scope for future work.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 11, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 3, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 8, 2024

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

May 16, 2024

Status Verified

May 1, 2024

Enrollment Period

1.6 years

First QC Date

May 3, 2024

Last Update Submit

May 14, 2024

Conditions

Keywords

Occupational Lung DiseasesEpidemiologyRespiratoryInfectionTuberculosisSilicosis

Outcome Measures

Primary Outcomes (1)

  • Change in chest radiography

    Rate of change of the ILO classification of pneumoconioses among cohort participants

    18-months

Secondary Outcomes (6)

  • Silicosis prevalence at baseline

    Baseline

  • TB prevalence at baseline

    Baseline

  • Clustering of TB cases

    18-months

  • Measurement of 'catastrophic' economic loss

    18-months

  • Use of C-reactive protein as a screening aid for TB

    Baseline

  • +1 more secondary outcomes

Study Arms (2)

Cross-sectional study

In the cross-sectional study group, we will enroll approximately 1400 miners and community members from an ongoing community-based, screening program, which is led by Kibong'oto Infectious Diseases Hospital (KIDH), and from incident TB cases from the local Mererani health centre and KIDH clinic.

Other: No intervention

Cohort group

We will enroll the prospective cohort group of 410 small-scale tanzanite miners from within the cross-sectional study group (nested). They will be sampled from specific mines chosen by a random stratified sample of mines.

Other: No intervention

Interventions

No intervention

Cohort groupCross-sectional study

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Tanzanite mines are near Mererani, Simanjaro District, Northern Tanzania. The district population is 178,683, with 13,450 in Mererani. Recent data suggests Mererani's population is around 18,300 due to regional growth. About 100 active licenses exist, with each mine employing 70 to 90 miners, totaling around 9,000 miners; earlier estimates were higher at 15,000. Healthcare is provided by Kibongo'oto Infectious Diseases Hospital, 60 km away, with one other clinic offering TB services. Recruitment for our survey is from a TB screening program, offering free CXR and Xpert tests via a mobile clinic rotating. We plan to include 5-10 mines in the study, focusing on diverse roles and exposures.

You may qualify if:

  • Age \> 18 years
  • Ability to provide informed consent
  • Miner or community member (defined as all individuals not directly involved in mining)
  • HIV positive and negative individuals
  • Age \> 18 years
  • Ability to provide informed consent
  • Current miner in an artisanal, small-scale tanzanite mine that is part of this study
  • Male
  • Mine exposure starting \<10 years ago
  • HIV positive and negative individuals

You may not qualify if:

  • \- Plans to move away from area in next 18 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kibong'oto Infectious Diseases Hospital

Sanya Juu, Kilimanjaro, PO Box, Tanzania

RECRUITING

Related Publications (6)

  • Howlett P, Mousa H, Said B, Mbuya A, Kon OM, Mpagama S, Feary J. Silicosis, tuberculosis and silica exposure among artisanal and small-scale miners: A systematic review and modelling paper. PLOS Glob Public Health. 2023 Sep 21;3(9):e0002085. doi: 10.1371/journal.pgph.0002085. eCollection 2023.

    PMID: 37733799BACKGROUND
  • Dennis E, Mussa H, Sanga MP, Howlett P, Nyakunga G. Silicosis and silicotuberculosis among respiratory hospital admissions: A cross-sectional survey in northern Tanzania. Afr J Thorac Crit Care Med. 2023 Sep 19;29(3):10.7196/AJTCCM.2023.v29i3.269. doi: 10.7196/AJTCCM.2023.v29i3.269. eCollection 2023.

    PMID: 37970570BACKGROUND
  • Mbuya AW, Mboya IB, Semvua HH, Msuya SE, Howlett PJ, Mamuya SH. Concentrations of respirable crystalline silica and radon among tanzanite mining communities in Mererani, Tanzania. Ann Work Expo Health. 2024 Jan 8;68(1):48-57. doi: 10.1093/annweh/wxad062.

    PMID: 37824745BACKGROUND
  • Rees D, Murray J. Silica, silicosis and tuberculosis. Int J Tuberc Lung Dis. 2007 May;11(5):474-84.

    PMID: 17439668BACKGROUND
  • Ehrlich R, Murray J, Rees D. Subradiological silicosis. Am J Ind Med. 2018 Nov;61(11):877-885. doi: 10.1002/ajim.22909. Epub 2018 Sep 21.

    PMID: 30239033BACKGROUND
  • Ehrlich R, Akugizibwe P, Siegfried N, Rees D. The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. BMC Public Health. 2021 May 20;21(1):953. doi: 10.1186/s12889-021-10711-1.

    PMID: 34016067BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Sputum samples for MTb culture and MTb DNA extraction Whole blood samples for haematology Serum samples for biochemistry and serum save

MeSH Terms

Conditions

SilicosisTuberculosisInfections

Condition Hierarchy (Ancestors)

PneumoconiosisLung Diseases, InterstitialLung DiseasesRespiratory Tract DiseasesLung InjuryOccupational DiseasesMycobacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and Mycoses

Central Study Contacts

Patrick J Howlett, MB ChB

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor Clinical Research Fellow

Study Record Dates

First Submitted

May 3, 2024

First Posted

May 8, 2024

Study Start

March 11, 2024

Primary Completion

October 1, 2025

Study Completion

December 1, 2025

Last Updated

May 16, 2024

Record last verified: 2024-05

Locations